Seeking Alpha

Celldex Therapeutics (CLDX) +6.1% premarket after announcing positive three-year survival data...

Celldex Therapeutics (CLDX) +6.1% premarket after announcing positive three-year survival data for its rindopepimut Phase 2 clinical program. Data suggests "a substantial and continuing survival benefit in comparison to independent control datasets," and strongly supports an ongoing Phase 3 clinical program, CLDX says.
From other sites
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs